FDA Scientists Opposed Trump Administration Move to Ease Access to Unproven Peptide Drugs Favored by RFK Jr.

A plan to loosen restrictions on certain injectable peptide drugs, championed by Health Secretary Robert F. Kennedy Jr., faced fierce opposition from most FDA scientific staff, according to six people familiar with the policy's development. The document, posted by the Department of Health and Human Services, covers peptides promoted for muscle building, injury healing, and energy boosting—claims that lack robust clinical evidence. Agency scientists had limited input in drafting the policy, raising concerns about bypassing standard safety and efficacy reviews. The move aligns with Kennedy’s long-standing skepticism of conventional drug approval processes and his promotion of alternative health products. Critics warn that easing access to unproven peptides could expose consumers to unknown risks, including contamination, improper dosing, and adverse reactions. Supporters argue it expands personal health freedom and accelerates access to potentially beneficial treatments. The clash highlights ongoing tensions between political appointees and career scientists over drug regulation priorities. The outcome may set a precedent for how the FDA handles other unapproved substances under the current administration.